KRAS and pancreatic neoplasm: Preclinical models included pancreatic cancer organoids (PDAC-1, PDAC-2, PDAC-R) derived from patient samples and genetically engineered KPC (Kras/p53/Cre) and KPNC (Kras/p53/Notch/Cre) mice [30].